Symbols / IBRX
IBRX Chart
About
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.40B |
| Enterprise Value | 10.00B | Income | -351.40M | Sales | 113.29M |
| Book/sh | -0.53 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 238.50 | PEG | — |
| P/S | 82.94 | P/B | -17.93 | P/C | — |
| EV/EBITDA | -44.16 | EV/Sales | 88.28 | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.41 | EPS next Y | 0.04 | EPS Growth | — |
| Revenue Growth | 4.07% | Earnings | 2026-05-11 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 99.33% |
| Oper. Margin | -132.38% | Profit Margin | 0.00% | Shs Outstand | 984.97M |
| Shs Float | 336.17M | Short Float | 40.85% | Short Ratio | 2.79 |
| Short Interest | — | 52W High | 12.43 | 52W Low | 1.83 |
| Beta | 0.02 | Avg Volume | 30.23M | Volume | 79.17M |
| Target Price | $13.50 | Recom | Strong_buy | Prev Close | $11.55 |
| Price | $9.54 | Change | -17.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.50
Mean price target
2. Current target
$9.54
Latest analyst target
3. DCF / Fair value
$13.50
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$9.54
Low
$7.00
High
$23.00
Mean
$13.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-02-23 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-02-19 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-02-17 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-26 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2026-01-23 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-23 | main | BTIG | Buy → Buy | $9 |
| 2026-01-20 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2026-01-20 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-16 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-13 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-16 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-12 | main | Jefferies | Buy → Buy | $9 |
| 2025-12-12 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-11 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-11-13 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-11-05 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-09-08 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-08-26 | main | D. Boral Capital | Buy → Buy | $24 |
- ImmunityBio: Disconnect Between Clinical Progress And Stock Performance (NASDAQ:IBRX) - Seeking Alpha Wed, 25 Feb 2026 12
- ImmunityBio (IBRX) Stock Explodes 500%+ in 2026 on ANKTIVA's 700% Revenue Surge - International Business Times Australia ue, 24 Feb 2026 17
- Why ImmunityBio Stock Is Soaring Again Today - Yahoo Finance Mon, 23 Feb 2026 18
- ImmunityBio Supersedes Expectations With Fivefold Revenue Increase - ImmunityBio (NASDAQ:IBRX) - Benzinga Wed, 25 Feb 2026 18
- ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Mon, 23 Feb 2026 15
- IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move - Stocktwits Wed, 25 Feb 2026 01
- IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth - Stocktwits ue, 24 Feb 2026 06
- Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more - CNBC Fri, 16 Jan 2026 08
- ImmunityBio Stock Is Up 18% This Week: Here’s What Global ANKTIVA Approvals Mean - TIKR.com hu, 26 Feb 2026 00
- ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus - TechStock² Wed, 25 Feb 2026 11
- ImmunityBio Stock (IBRX) Opinions on Saudi Launch and EU Approval - Quiver Quantitative Wed, 25 Feb 2026 17
- Why ImmunityBio (IBRX) Is Up 65.3% After ANKTIVA’s European Approval And New Regional Partnerships - simplywall.st ue, 24 Feb 2026 04
- Why ImmunityBio Stock Is Soaring Again Today - The Motley Fool Mon, 23 Feb 2026 17
- IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook - Meyka Wed, 25 Feb 2026 09
- ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption - Yahoo Finance Wed, 25 Feb 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | 74500.0 | — | Conversion of Exercise of derivative security at price 2.98 per share. | SELECKY CHRISTOBEL E. | Director | — | 2026-02-23 00:00:00 | D |
| 1 | 175000 | 1783602.0 | — | Sale at price 9.25 - 10.25 per share. | SIMON BARRY J. M.D. | Director | — | 2026-02-23 00:00:00 | D |
| 2 | 25000 | 250000.0 | — | Sale at price 10.00 per share. | SELECKY CHRISTOBEL E. | Director | — | 2026-02-23 00:00:00 | D |
| 3 | 15243 | nan | — | — | SIMON BARRY J. M.D. | Director | — | 2026-02-20 00:00:00 | D |
| 4 | 274122 | nan | — | — | ADCOCK RICHARD | Chief Executive Officer | — | 2026-02-10 00:00:00 | D |
| 5 | 82236 | nan | — | — | SACHS DAVID C | Chief Financial Officer | — | 2026-02-10 00:00:00 | D |
| 6 | 5482 | nan | — | — | LAUER REGAN J | Officer | — | 2026-02-10 00:00:00 | D |
| 7 | 274122 | nan | — | — | SOON-SHIONG PATRICK | Officer, Director and Beneficial Owner | — | 2026-02-10 00:00:00 | D |
| 8 | 75000 | 223500.0 | — | Conversion of Exercise of derivative security at price 2.98 per share. | SELECKY CHRISTOBEL E. | Director | — | 2026-01-20 00:00:00 | D |
| 9 | 151967 | 989364.0 | — | Sale at price 6.48 - 6.54 per share. | SIMON BARRY J. M.D. | Director | — | 2026-01-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -3.30K | 1.47M | -1.33M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -303.44M | -394.24M | -358.86M | -315.82M |
| TotalUnusualItems | 39.01M | -48.22M | 6.98M | -4.94M |
| TotalUnusualItemsExcludingGoodwill | 39.01M | -48.22M | 6.98M | -4.94M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -413.56M | -583.20M | -416.57M | -346.79M |
| ReconciledDepreciation | 17.55M | 18.51M | 18.26M | 14.24M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | 0.00 | |
| EBITDA | -264.43M | -478.66M | -351.88M | -320.75M |
| EBIT | -281.99M | -497.18M | -370.14M | -334.99M |
| NetInterestIncome | -151.93M | -128.34M | -60.81M | -14.01M |
| InterestExpense | 131.66M | 86.72M | 47.15M | 14.85M |
| InterestIncome | 2.40M | 863.00K | 2.71M | 836.00K |
| NormalizedIncome | -452.57M | -534.98M | -422.08M | -343.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -413.56M | -583.20M | -416.57M | -346.79M |
| TotalExpenses | 358.93M | 361.99M | 350.86M | 331.21M |
| TotalOperatingIncomeAsReported | -344.18M | -362.25M | -351.30M | -330.28M |
| DilutedAverageShares | 700.44M | 508.64M | 399.90M | 389.23M |
| BasicAverageShares | 697.31M | 508.64M | 399.90M | 389.23M |
| DilutedEPS | -0.62 | -1.15 | -1.04 | -0.89 |
| BasicEPS | -0.59 | -1.15 | -1.04 | -0.89 |
| DilutedNIAvailtoComStockholders | -413.56M | -583.20M | -416.57M | -346.79M |
| NetIncomeCommonStockholders | -413.56M | -583.20M | -416.57M | -346.79M |
| NetIncome | -413.56M | -583.20M | -416.57M | -346.79M |
| MinorityInterests | 81.00K | 656.00K | 753.00K | 3.06M |
| NetIncomeIncludingNoncontrollingInterests | -413.64M | -583.85M | -417.32M | -349.85M |
| NetIncomeContinuousOperations | -413.64M | -583.85M | -417.32M | -349.85M |
| TaxProvision | 0.00 | -40.00K | 34.00K | 9.00K |
| PretaxIncome | -413.64M | -583.89M | -417.29M | -349.84M |
| OtherIncomeExpense | 82.46M | -94.19M | -5.86M | -5.55M |
| OtherNonOperatingIncomeExpenses | 43.46M | -38.43M | -736.00K | 193.00K |
| SpecialIncomeCharges | 0.00 | -886.00K | -681.00K | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 886.00K | 681.00K | 0.00 |
| SecuritiesAmortization | -1.84M | 1.49M | 488.00K | |
| EarningsFromEquityInterest | 0.00 | -7.55M | -12.11M | -803.00K |
| GainOnSaleOfSecurity | 39.01M | -47.33M | 7.66M | -4.94M |
| NetNonOperatingInterestIncomeExpense | -151.93M | -128.34M | -60.81M | -14.01M |
| TotalOtherFinanceCost | 22.67M | 42.48M | 16.37M | |
| InterestExpenseNonOperating | 131.66M | 86.72M | 47.15M | 14.85M |
| InterestIncomeNonOperating | 2.40M | 863.00K | 2.71M | 836.00K |
| OperatingIncome | -344.18M | -361.36M | -350.62M | -330.28M |
| OperatingExpense | 358.93M | 361.99M | 350.86M | 331.21M |
| ResearchAndDevelopment | 190.14M | 232.37M | 248.15M | 195.96M |
| SellingGeneralAndAdministration | 168.78M | 129.62M | 102.71M | 135.26M |
| GrossProfit | 14.74M | 622.00K | 240.00K | |
| CostOfRevenue | 0.00 | 0.00 | 0.00 | |
| TotalRevenue | 14.74M | 622.00K | 240.00K | 934.00K |
| OperatingRevenue | 14.15M | 0.00 | 0.00 | 934.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 163.80K | 163.80K | 163.80K | 163.80K |
| OrdinarySharesNumber | 852.90M | 670.87M | 421.57M | 397.83M |
| ShareIssued | 853.07M | 671.03M | 421.73M | 397.99M |
| NetDebt | 318.45M | 416.08M | 568.53M | 424.48M |
| TotalDebt | 504.17M | 726.72M | 723.77M | 645.66M |
| TangibleBookValue | -505.03M | -604.08M | -467.33M | -243.59M |
| InvestedCapital | -27.22M | 94.55M | 225.84M | 363.41M |
| WorkingCapital | 129.64M | 235.80M | -360.28M | -34.65M |
| NetTangibleAssets | -505.03M | -604.08M | -467.33M | -243.59M |
| CapitalLeaseObligations | 42.29M | 45.19M | 50.60M | 40.08M |
| CommonStockEquity | -489.10M | -586.99M | -447.33M | -242.17M |
| TotalCapitalization | -27.22M | 94.55M | -206.06M | 64.18M |
| TotalEquityGrossMinorityInterest | -488.13M | -585.94M | -449.82M | -243.91M |
| MinorityInterest | 969.00K | 1.05M | -2.49M | -1.74M |
| StockholdersEquity | -489.10M | -586.99M | -447.33M | -242.17M |
| GainsLossesNotAffectingRetainedEarnings | 1.20M | 10.00K | 183.00K | 4.00K |
| RetainedEarnings | -3.38B | -2.96B | -2.38B | -1.96B |
| AdditionalPaidInCapital | 2.88B | 2.37B | 1.93B | 1.72B |
| CapitalStock | 85.00K | 67.00K | 42.00K | 40.00K |
| CommonStock | 85.00K | 67.00K | 42.00K | 40.00K |
| TotalLiabilitiesNetMinorityInterest | 871.06M | 1.09B | 812.18M | 712.82M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 816.12M | 1.03B | 311.31M | 343.83M |
| OtherNonCurrentLiabilities | 285.04M | 156.52M | 457.00K | 411.00K |
| DerivativeProductLiabilities | 34.38M | 154.10M | 21.64M | 0.00 |
| NonCurrentDeferredLiabilities | 162.00K | |||
| NonCurrentDeferredTaxesLiabilities | 162.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 496.70M | 721.48M | 289.22M | 343.42M |
| LongTermCapitalLeaseObligation | 34.82M | 39.94M | 47.95M | 37.07M |
| LongTermDebt | 461.88M | 681.54M | 241.27M | 306.35M |
| CurrentLiabilities | 54.94M | 58.28M | 500.86M | 369.00M |
| OtherCurrentLiabilities | 952.00K | 716.00K | 1.63M | 2.60M |
| CurrentDebtAndCapitalLeaseObligation | 7.47M | 5.24M | 434.55M | 302.25M |
| CurrentCapitalLeaseObligation | 7.47M | 5.24M | 2.65M | 3.01M |
| CurrentDebt | 431.90M | 299.24M | ||
| OtherCurrentBorrowings | 431.90M | 299.24M | ||
| CurrentNotesPayable | 299.24M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 15.03M | 17.59M | 18.11M | 13.93M |
| PayablesAndAccruedExpenses | 31.50M | 34.73M | 46.57M | 50.22M |
| CurrentAccruedExpenses | 24.60M | 24.40M | 22.09M | 34.86M |
| Payables | 6.90M | 10.33M | 24.48M | 15.36M |
| DuetoRelatedPartiesCurrent | 173.00K | 1.14M | 3.47M | 3.94M |
| AccountsPayable | 6.72M | 9.20M | 21.02M | 11.42M |
| TotalAssets | 382.93M | 504.45M | 362.36M | 468.91M |
| TotalNonCurrentAssets | 198.35M | 210.37M | 221.78M | 134.56M |
| OtherNonCurrentAssets | 4.83M | 2.88M | 4.86M | |
| NonCurrentNoteReceivables | 7.13M | 6.88M | 6.63M | 6.38M |
| InvestmentsAndAdvances | 0.00 | 891.00K | 840.00K | 7.60M |
| OtherInvestments | 4.86M | 6.78M | ||
| InvestmentinFinancialAssets | 0.00 | 891.00K | 840.00K | 822.00K |
| AvailableForSaleSecurities | 891.00K | 840.00K | 822.00K | |
| LongTermEquityInvestment | 840.00K | 822.00K | ||
| GoodwillAndOtherIntangibleAssets | 15.93M | 17.09M | 20.00M | 1.42M |
| OtherIntangibleAssets | 15.93M | 17.09M | 20.00M | 1.42M |
| NetPPE | 170.46M | 182.62M | 189.45M | 119.17M |
| AccumulatedDepreciation | -99.59M | -84.38M | -69.25M | -53.07M |
| GrossPPE | 270.05M | 267.00M | 258.70M | 172.24M |
| Leases | 73.13M | 72.55M | 68.71M | 62.48M |
| ConstructionInProgress | 86.42M | 84.44M | 72.69M | 16.57M |
| OtherProperties | 106.94M | 106.46M | 113.73M | 90.59M |
| MachineryFurnitureEquipment | 3.56M | 3.56M | 3.56M | 2.60M |
| BuildingsAndImprovements | 0.00 | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 184.59M | 294.08M | 140.58M | 334.35M |
| OtherCurrentAssets | 1.30M | 2.62M | 2.90M | 2.96M |
| PrepaidAssets | 22.55M | 21.83M | 28.60M | 12.94M |
| Inventory | 8.27M | 0.00 | ||
| FinishedGoods | 767.00K | 0.00 | ||
| WorkInProcess | 7.50M | 0.00 | ||
| RawMaterials | 0.00 | 0.00 | ||
| Receivables | 2.65M | 3.17M | 1.89M | 1.33M |
| OtherReceivables | 1.15M | |||
| DuefromRelatedPartiesCurrent | 293.00K | 2.02M | 1.89M | 1.33M |
| AccountsReceivable | 2.36M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 149.81M | 266.46M | 107.18M | 317.12M |
| OtherShortTermInvestments | 6.38M | 1.01M | 2.54M | 136.01M |
| CashAndCashEquivalents | 143.43M | 265.45M | 104.64M | 181.10M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -398.12M | -397.34M | -436.90M | -307.98M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -64.00K | -77.00K | -58.00K | 0.00 |
| IssuanceOfDebt | 0.00 | 258.70M | 174.12M | 338.50M |
| IssuanceOfCapitalStock | 111.36M | 110.10M | 60.43M | 164.53M |
| CapitalExpenditure | -6.89M | -30.58M | -99.39M | -33.56M |
| InterestPaidSupplementalData | 92.32M | 77.19M | 35.44M | 2.11M |
| IncomeTaxPaidSupplementalData | 15.00K | 8.00K | 2.00K | 9.00K |
| EndCashPosition | 143.91M | 265.79M | 104.97M | 181.28M |
| BeginningCashPosition | 265.79M | 104.97M | 181.28M | 35.09M |
| EffectOfExchangeRateChanges | -23.00K | -292.00K | 284.00K | 48.00K |
| ChangesInCash | -121.85M | 161.11M | -76.60M | 146.14M |
| FinancingCashFlow | 281.63M | 558.34M | 233.61M | 505.44M |
| CashFlowFromContinuingFinancingActivities | 281.63M | 558.34M | 233.61M | 505.44M |
| NetOtherFinancingCharges | 96.96M | 192.76M | -339.00K | 1.02M |
| ProceedsFromStockOptionExercised | 73.38M | -3.15M | -542.00K | 1.40M |
| NetCommonStockIssuance | 111.36M | 110.10M | 60.43M | 164.53M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 111.36M | 110.10M | 60.43M | 164.53M |
| NetIssuancePaymentsOfDebt | -64.00K | 258.62M | 174.07M | 338.50M |
| NetShortTermDebtIssuance | 258.70M | 174.12M | 338.50M | |
| ShortTermDebtIssuance | 258.70M | 174.12M | 338.50M | |
| NetLongTermDebtIssuance | -64.00K | 258.62M | 174.07M | 0.00 |
| LongTermDebtPayments | -64.00K | -77.00K | -58.00K | 0.00 |
| LongTermDebtIssuance | 0.00 | 258.70M | 174.12M | 338.50M |
| InvestingCashFlow | -12.25M | -30.47M | 27.30M | -84.89M |
| CashFlowFromContinuingInvestingActivities | -12.25M | -30.47M | 27.30M | -84.89M |
| NetOtherInvestingChanges | -1.00M | |||
| NetInvestmentPurchaseAndSale | -4.36M | 114.00K | 127.69M | -71.82M |
| SaleOfInvestment | 136.61M | 10.47M | 162.00M | 69.93M |
| PurchaseOfInvestment | -140.97M | -10.36M | -34.31M | -141.75M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -1.00M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -1.00M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -21.23M | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -21.23M | 0.00 |
| NetPPEPurchaseAndSale | -6.89M | -30.58M | -78.16M | -13.06M |
| SaleOfPPE | 0.00 | 0.00 | 20.50M | |
| PurchaseOfPPE | -6.89M | -30.58M | -78.16M | -33.56M |
| OperatingCashFlow | -391.24M | -366.76M | -337.51M | -274.42M |
| CashFlowFromContinuingOperatingActivities | -391.24M | -366.76M | -337.51M | -274.42M |
| ChangeInWorkingCapital | -19.42M | 3.98M | -8.00M | -19.11M |
| ChangeInOtherWorkingCapital | 763.00K | -1.13M | -1.23M | -10.19M |
| ChangeInOtherCurrentLiabilities | -5.47M | -2.98M | -4.32M | -4.16M |
| ChangeInOtherCurrentAssets | -1.11M | 1.91M | 2.00M | -3.98M |
| ChangeInPayablesAndAccruedExpense | -4.67M | 213.00K | 12.10M | 1.47M |
| ChangeInAccruedExpense | -1.51M | 6.69M | 4.10M | 5.18M |
| ChangeInPayable | -3.17M | -6.48M | 8.00M | -3.72M |
| ChangeInAccountPayable | -3.17M | -6.48M | 8.00M | -3.72M |
| ChangeInPrepaidAssets | 1.70M | 5.96M | -16.56M | -2.25M |
| ChangeInInventory | -8.27M | 0.00 | 0.00 | |
| ChangeInReceivables | -2.36M | 0.00 | 0.00 | |
| ChangesInAccountReceivables | -2.36M | 0.00 | 0.00 | |
| OtherNonCashItems | 24.13M | 95.50M | 35.31M | 18.10M |
| StockBasedCompensation | 34.43M | 49.16M | 40.18M | 57.18M |
| UnrealizedGainLossOnInvestmentSecurities | 632.00K | 1.59M | 4.19M | 4.62M |
| AssetImpairmentCharge | 0.00 | 886.00K | 2.01M | 0.00 |
| AmortizationOfSecurities | -1.49M | -137.00K | 1.32M | 403.00K |
| DeferredTax | -4.00K | -8.00K | ||
| DeferredIncomeTax | -4.00K | -8.00K | ||
| DepreciationAmortizationDepletion | 17.55M | 18.51M | 18.26M | 14.24M |
| DepreciationAndAmortization | 17.55M | 18.51M | 18.26M | 14.24M |
| OperatingGainsLosses | -33.43M | 47.60M | -13.46M | 803.00K |
| EarningsLossesFromEquityInvestments | 803.00K | |||
| GainLossOnInvestmentSecurities | -33.43M | 47.60M | -13.46M | |
| NetIncomeFromContinuingOperations | -413.64M | -583.85M | -417.32M | -349.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IBRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|